Are vaccines against COVID-19 tailored to the most vulnerable people?

Antonelli Incalzi, Raffaele; Trevisan, Caterina; Del Signore, Susanna; Volpato, Stefano; Fumagalli, Stefano; Monzani, Fabio; Bellelli, Giuseppe; Gareri, Pietro; Mossello, Enrico; Malara, Alba; Coin, Alessandra; Zia, Gianluca; Ranhoff, Anette Hylen

doi:10.1016/j.vaccine.2021.03.066

The pharmaceutical industry and upstream regulatory agencies should support and pursue a real-life validation of vaccines against COVID-19 in the most at-risk population. To the current state, it is therefore essential to monitor the effectiveness, safety, and immunogenicity of COVID-19 vaccines in the most vulnerable categories, including the frailest ones as well as patients with cancer, immunodepression, chronic degenerative diseases, or developmental disabilities. Accordingly, some multicentre initiatives, such as GeroCovid Vax[, are monitoring vaccinated nursing home residents over time and will provide reliable information on shorter and longer-term safety and efficacy of COVID-19 vaccines in such vulnerable population

Are vaccines against COVID-19 tailored to the most vulnerable people? / Antonelli Incalzi, Raffaele; Trevisan, Caterina; Del Signore, Susanna; Volpato, Stefano; Fumagalli, Stefano; Monzani, Fabio; Bellelli, Giuseppe; Gareri, Pietro; Mossello, Enrico; Malara, Alba; Coin, Alessandra; Zia, Gianluca; Ranhoff, Anette Hylen. - In: VACCINE. - ISSN 0264-410X. - ELETTRONICO. - 39:(2021), pp. 2325-2327. [10.1016/j.vaccine.2021.03.066]